polarean Regulatory News (POLX)

29 April 2019

Polarean Imaging Plc 

("Polarean" or the "Company")

Appointment of Chief Financial Officer

Polarean Imaging plc (AIM: POLX) Polarean Imaging plc (AIM: POLX), the clinical stage medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces the appointment of Charles (Chuck) Osborne, Jr as Chief Financial Officer (CFO) with immediate effect. Chuck Osborne's role is a non-board appointment.

Mr. Osborne joins the Company from Innocrin Pharmaceuticals Inc ("Innocrin"), a privately held oncology therapeutics company where he was CFO since 2015. Prior to his role at Innocrin, Mr. Osborne was CFO of Scynexis Inc, a publicly traded anti-infective company between 2003 and 2015. Mr. Osborne holds a Bachelor of Science degree in Business Administration, with a Concentration in Accounting, from University of North Carolina. He is a Certified Public Accountant and began his accounting career at Deloittie & Touche in 1988.

Mr. Osborne will replace the Company's current CFO Bill Patrick, who will stay with Polarean in the role of Financial Controller to Polarean Inc, the Company's wholly owned subsidiary.

Richard Hullihen, CEO of Polarean Imaging, commented on the appointment: "We are delighted to welcome Chuck to Polarean's management team. Chuck's previous capital markets experience coupled with his knowledge of financial operations within the pharmaceutical industry will ensure strong leadership of the Company's financial function.

"On behalf of the Board, I would like to thank Bill Patrick for all his efforts and input to date both operationally and financially through the Company's admission to AIM last year and in the period since. Mr Patrick's involvement with the Company will continue with his new role of Financial Controller for Polarean Inc."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries: